Title | Exploiting synthetic lethal interactions for targeted cancer therapy. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Reinhardt, HC, Jiang, H, Hemann, MT, Yaffe, MB |
Journal | Cell Cycle |
Volume | 8 |
Issue | 19 |
Pagination | 3112-9 |
Date Published | 2009 Oct 1 |
ISSN | 1551-4005 |
Keywords | Animals, BRCA1 Protein, BRCA2 Protein, Cell Cycle Proteins, DNA Damage, DNA Repair, DNA-Binding Proteins, Humans, Mice, Neoplasms, Oncogenes, Poly(ADP-ribose) Polymerases, Protein-Serine-Threonine Kinases, Tumor Suppressor Protein p53, Tumor Suppressor Proteins |
Abstract | Emerging data suggests that synthetic lethal interactions between mutated oncogenes/tumor suppressor genes and molecules involved in DNA damage signaling and repair can be therapeutically exploited to preferentially kill tumor cells. In this review, we discuss the concept of synthetic lethality, and describe several recent examples in which this concept was successfully implemented to target tumor cells in culture, in mouse models, and in human cancer patients. |
Alternate Journal | Cell Cycle |
PubMed ID | 19755856 |
PubMed Central ID | PMC3057180 |
Grant List | CA112967 / CA / NCI NIH HHS / United States ES015339 / ES / NIEHS NIH HHS / United States GM68762 / GM / NIGMS NIH HHS / United States P50 GM068762-08 / GM / NIGMS NIH HHS / United States R01 ES015339-05 / ES / NIEHS NIH HHS / United States U54 CA112967-03 / CA / NCI NIH HHS / United States U54-CA112967-03 / CA / NCI NIH HHS / United States |